Caris Life Sciences raises 2026 revenue guidance to $1.04-$1.05 billion
FROM THE WIRE · PRNEWSWIRE.COM
Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29% IRVING…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRaised revenue guidance for a mid-cap oncology testing company, with 27 percent growth in the quarter.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third quarter 2026 revenue was $275.4 million, up 27 percent year over year.
- 022026 revenue guidance was raised to $1.04-$1.05 billion.
- 03Volume included about 61,500 clinical cases and over 358,000 oncology tests.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets